4SC AG, a clinical-stage biopharmaceutical company, engages in developing small-molecule drugs that target key indications in cancer with high unmet medical needs.
The last earnings update was 37 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
4SC. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
4SC's earnings available for a low price, and how does
this compare to other companies in the same industry?
Unable to determine if 4SC is high growth as no earnings estimate data is available.
Unable to determine if 4SC is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
4SC's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Jason Loveridge, B.Sc, PhD, FRSM, has been Corporate Advisor of Resonance Health Limited since June 30, 2017. Dr. Loveridge has been Chairman of Management Board and Chief Executive Officer of 4SC AG since September 21, 2016. Dr. Loveridge is the Owner of Warambi Sari. He serves as an Executive Director of Warambi Sari. Dr. Loveridge served as Chief Executive Officer and Executive Director of Arthro Kinetics plc since November 3, 2006. He served as the Chief Executive Officer of Genable Technologies Limited. He has been working in the biotech and medtech industries for over 20 years. Since leaving the investment arena in 2005, Dr. Loveridge has been directly involved in the management of a number of small innovative companies in the medical arena, specifically in restructuring, refinancing and in product commercialisation. He has more than 20 years of international experience across Europe, Asia and the US in senior management positions in life sciences companies and as an investment professional dealing in both privately held and publicly traded companies. He established a lengthy track record of successful participation in European, US and Israeli based healthcare companies. He served as an Interim Chairman of Actinogen Medical Limited since November 30, 2016 until March 01, 2017. He was Non-Executive Director of Actinogen Medical Limited from December 1, 2014 to November 28, 2018. He serves as a Director of Parvulus Suiss SA, JDS BioPharma Limited and Anaconda SAS. He served as a Non-Executive Director of Resonance Health Limited since February 7, 2013 until June 30, 2017. He served as a Non Executive Director at Arthro from January 31, 2006 to November 3, 2006. He served as a Member of Supervisory Board at Biofrontera AG until July 1, 2009. Dr. Loveridge is an Active Venture Investor. Dr. Loveridge graduated in Biochemistry and Microbiology from the University of New South Wales, Australia and holds a Ph.D. in Biochemistry from the University of Adelaide, Australia.
Jason's compensation has increased whilst company is loss making.
Jason's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure of the
management team in years:
The tenure for the 4SC management team is about average.
4SC AG, a clinical-stage biopharmaceutical company, engages in developing small-molecule drugs that target key indications in cancer with high unmet medical needs. The company’s drugs are intended to provide patients with various treatment options. Its pipeline is protected by a portfolio of patents and comprises three principal drug candidates that are in various stages of development. The company’s products in clinical development stage include Resminostat, an orally administered histone deacetylase inhibitor that is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma and biliary tract cancer; and Domatinostat, an orally administered small molecule, which is in Phase Ib/II clinical trial for the treatment of melanoma and Phase II clinical trial for the treatment of gastrointestinal tumor. Its product in preclinical stage includes 4SC-208, a small molecule targeting two kinases crucial for Hedgehog/GLI signaling. The company also out-licenses its products to pharma and biotech companies for the treatment of cancer. 4SC AG was founded in 1997 and is headquartered in Planegg, Germany.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.